RMZ digs into why weight loss results on tirzepatide vary so widely, with some people losing double what others do.
Recap by typeshit. Full story at RMZ.
A comment-for-link Instagram post saying trials of semaglutide, tirzepatide and retatrutide showed up to 28% weight loss. Little detail beyond that.
Real-world records shown at EASD 2026 had 24.1% of tirzepatide users losing 15% or more in a year, versus about 9% on semaglutide, GlobalData reports.
Survey data on 3,615 US adults showed about 30% lower odds of GLP-1 use among cancer survivors, despite more heart and kidney disease. Causes remain unclear.
The retatrutide rival from United Biotechnology led to weight loss of up to 9.8% at 24 weeks in 211 Chinese adults, beating semaglutide's 4.8%, per Cell Metabolism.
A woman with bipolar disorder developed tremor and slurred speech three weeks into Zepbound. An outside expert advises checking lithium levels early, not avoiding the drugs.
A shared piece on how the spread of GLP-1 drugs could shape how people who aren't taking them feel. Only the headline is available here.
Loading…